About Henlius-Management Team

Wenjie Zhang

Chairman
Executive Director and CEO

Mr. Wenjie Zhang is the Chairman, Executive Director, and Chief Executive Officer of Henlius. Mr. Zhang has nearly 30 years of operational experience in the pharmaceutical industry.

Before joining Henlius in March 2019, Mr. Zhang served as General Manager of Amgen China where he was leading the company’s overall efforts in expanding the business into the Chinese market. During his tenure as General Manager, Amgen China has effectively built up its commercial infrastructure, organization, and competency. He successfully launched Repatha® (evolocumab), Amgen’s first product in China. Prior to that, Mr. Zhang was the Executive Director, Marketing for Amgen Japan and Asia Pacific region, responsible for marketing and business development in China, Japan, Australia and other Asia Pacific countries and regions.

Prior to Amgen, Mr. Zhang worked as Vice President, Oncology for Roche China from 2010 to 2014, where he significantly grew the Roche oncology portfolio including Avastin® (bevacizumab), Tarceva®(erlotinib) and MabThera® (rituximab) in the China market. He also led Roche China oncology franchise in pipeline planning, franchise strategy, and franchise marketing.

Before then, Mr. Zhang served as the Head of Business Development at Bayer Schering Pharma, Asia Pacific Headquarters, Product Manager of US Marketing, Business Development Manager and Deputy Director of Global Marketing at Bayer Pharmaceuticals USA. In this role, he led the fastest-growing business unit within Bayer China. He also had dual responsibility as Head of the same business unit for the Asia Pacific region. He succeeded in launching multiple products in China including Nexavar®, Kogenate® and Betaferon®.

Mr. Zhang holds an MBA degree from Yale University and a B.S. degree in microbiology from Shandong University.
Jason Zhu

President

Mr. Jason Zhu, President of the Company, is responsible for the company’s global product development and management of certain functional departments.Jason has more than 20 years in clinical research industry. He had cooperated with over 70 China local pharmaceutical and biotech companies and led the design and execution of over 100 phase I to IV clinical trials. Prior to joining Henlius, Jason was Founder and CEO of PPC China, Global Vice President of IQVIA, China GM of Omnicare. Jason had previously worked as a physician in Huashan Hospital for two years. Jason holds a bachelor degree in Clinical Medicine form Shanghai Medical College of Fudan University and an EMBA degree from CKGSB.
Wei Huang

Chief Operation Officer
SVP

Ms. Wei Huang, Chief Operation Officer and Senior Vice President, responsible for commercialized production and delivery, and construction of Songjiang Site. Ms. Huang holds Bachelor degree from East China University of Science and Technology in Biochemical Engineering, Master degree from University of Maryland in Chemical and Biochemical Engineering. Prior to joining Henlius, Ms. Huang has Senior management and leadership experience in pharmaceutical and biotechnology industry spanning over twenty-five years in process development, technology transfer, manufacturing, process and facility design, capital project execution, and quality system implementation.
James Guo

SVP

Mr. James Guo, Senior Vice President, graduated from Genetics and Genetic Engineering Department of Fudan University, and holds a MBA degree from Zhejiang University. He has previously served as research manager and chief engineer in Hangzhou Jiuyuan Gene Engineering Co., Ltd., Hangzhou Taishi Biotechnology Co., Ltd. and Shanghai Chemo Wanbang Biopharma Co., Ltd. James is experienced in biopharmaceutical development and production, and familiar with all types of national laws and regulations. He has been involved in the development of a Category II new drug, the first listed recombinant human granulocyte colony-stimulating factor (rhG-CSF) injection in China. He was awarded Shanghai Labor Medal, Outstanding Technology Development Talent of Hangzhou, Second Prize for Science and Technology Progress Award of Zhejiang Province and First Prize for Science and Technology Progress Award of Hangzhou. Under his leadership, Henlius was awarded 2021 National Worker Pioneer, 2021 Shanghai Worker Pioneer, 2020 Shanghai Model Group and 2019 Shanghai Worker Pioneer.
In addition, he is the member of the Pharmaceutical Innovation Investment Specialty Committee of China Pharmaceutical Innovation and Research Development Association (PhIRDA), the vice-chairman of Shanghai Biopharmaceutics Industry Association (SBIA) and the member of the 9th council of Shanghai Pharmaceutical Profession Association (SPPA).
Jifeng Zhang

Chief Technology Officer
SVP

Dr. Jifeng Zhang, Chief Technology Officer and Senior Vice President, responsible for driving biopharmaceutical product and process development, and biologics technology platforms at Henlius. Dr. Zhang has more than 20 years of experience in biologics drug development, from target validation to clinical trials and commercialization. Dr. Zhang has senior management and leadership experience in global pharmaceutical and biotechnology companies. He has published extensively in the fields of pharmaceutical chemistry, protein chemistry and biophysics. He holds both Bachelor degree in Chemistry and Ph. D. in Analytical Chemistry from Purdue University. He did his postdoctoral research in Biotechnology Process Engineering Center at MIT.
Kurt Yu

Chief Commercial Officer
VP

Mr. Kurt Yu, Chief Commercial Officer and Vice President of the Company, leads the marketing team and is responsible for the marketing strategy development, new product launch preparation, marketing activity planning and execution. He also takes charge of Pricing and Market Access, Distribution Management, Medical Affairs and Key Account, etc. Prior to joining Henlius, Mr. Yu has over 20 years’ experience in sales and central marketing management (for Glaxo Wellcome, Roche and Amgen) with different roles including medical representative, product manager, district sales manager, marketing manager, and marketing director/ head. He has rich experience in portfolio management, marketing strategy development, new product launch etc.

Mr. Yu graduated from Shanghai Medical University with bachelor degree in pharmaceutical chemistry. Then he obtained the EMBA degree from Fudan University.
Gino Li

Chief Financial Officer
VP

Mr. Gino Li, Chief Financial Officer and Vice President, is responsible for listing investment management, market value management and financial operation management. Previously, Mr. Li served as vice president and the general manager of investor relations and capital development department of Fosun Pharma. Mr. Li obtained a Bachelor of Science degree in Pharmacy from Sichuan University in 2004, a Master of Science degree from the University of Huddersfield in the U.K. in 2006, and a master’s degree from the IMBA Programme of Fudan University – Hong Kong University in 2016.
Jessie LI

Chief Human Resource Officer
VP

Ms. Jessie LI, Chief Human Resource Officer and Vice President, is responsible for overall HR strategy, organization development, talent strategy. Ms. Jessie LI brings with her over 20 years of HR management experiences, and prior to joining Henlius, she worked in TCCP, Astra Zeneca, De Lage Landen, Kodak Healthgroup/Carestream as HRVP, Executive HR Director, Head of China HR. Ms. Jessie LI holds Bachelor degree from Shandong Finance University in International Finance in 1998, and MBA from Shanghai University of Finance and Economics – Webster University in 2002
Ping Cao

Chief Business Officer
VP of Business Development

Ms. Ping Cao, Chief Business Officer and Vice President of Business Development, graduated from Tianjin University with a BS in Material Science & Engineering and MS in Chemical Engineering and also obtained her MS in Organic Chemistry at Michigan State University. She previously worked at Tyger Scientific, Ferro, Bristol-Myer Squibb (BMS) and Abzena, and held positions of Director of Sales and Marketing, Sr. Manager of Business Development, Associate Director of Global Manufacturing and Supply Chain, and Sr. Director of Business Development. At Tyger Scientific, Ms. Cao increased the business revenue 600% in 4 years. At BMS, she was responsible for global business development at CMO (contract manufacture operation) and accomplished significant sales growth. Then Ms. Cao joined business development team focusing on technology transactions. She evaluated, negotiated and executed 36 technology collaboration deals to expedite the company’s drug discovery and development process. As a reward for her accomplishment, Ms. Cao received the Distinguished Employee Award, Innovation Award etc. at BMS. At Abzena, she developed and executed the business strategy of offering integrated contract manufacture service of biologics and antibody drug conjugates based on company core technologies of antibody drug conjugation and humanization, which greatly enhanced the company’s business growth worldwide.
Wallis Zeng

VP of Oncology Business Unit

Mr. Wallis Zeng, Vice President of Sales, graduated from Gannan Medical University, majoring in clinical medicine.

Mr. Zeng is responsible for the sales strategy development, establishing and leading the sales team to achieve the annual sales targets. Prior to joining Henlius, he served as regional sales manager at MSD, national sales director at Roche, general manager at Evergrande Health and sales director at AZ. So far, he has about 30 years’ working experience. Mr. Zeng has rich experience in sales strategy development and sales team management.
Ming Yang

GM of Immune-Oncology Business Unit

Mr. Ming Yang, General Manager of Immune-Oncology Business Unit, is responsible for sales strategy development, establishing and managing the sales team of Serplulimab and leading the team to achieve the annual commercialization targets. Before joining Henlius, Ming served as important positions of many large multinational enterprises, such as Bristol-Myers Squibb, AstraZeneca, Roche, and Bayer. He has more than 20 years working experience in tumor immunity filed and led some blockbuster product launches in China such as Opdivo. Mr. Yang has rich experience in sales strategy development, commercial operation, and sales system establishment.
Yongqiang Shan

GM of Shanghai Innovation Center

Dr. Yongqiang Shan, General Manager of Shanghai Innovation Center, responsible for crafting and implementing strategy and operation of early research and development in China.

Dr. Yongqiang Shan has nearly 20 years’ experience in the research and development of new drugs, leading and participating in the research and development of many new lead and clinical candidate drugs, including small molecular compounds, monoclonal antibodies, recombinant proteins, and small interfering nucleic acids. Prior to joining Henlius, he was Vice President of Translational Science and Head of Shanghai R&D Center of HighTide Therapeutics, Head of Discovery Biology of Hengrui Pharmaceutical, Head of Early Research and Development of Hua Medicine, and Scientist of China Novartis Institute for Biomedical Research. Before that, he worked in Chinese Academy of Medical Sciences, Institute of Molecular Medicine of Peking University, and Chinese National Human Genome Center, Beijing, focusing on drug research and development. Dr. Yongqiang Shan holds Ph.D in Molecular Pharmacology from Tsinghua University and Peking Union Medical College, and Bachelor of Clinical Medicine and Master of Molecular Biology from China Medical University.
Arthur Sheng

GM of Global Strategy & PMO

The GM of Global Strategy & PMO. He is leading the company’s overall strategy development, including R&D strategy, portfolio management, manufacture & supply chain, commercialization and PMO. Prior to Henlius, he has been working for GSK, Roche Pharma, Roche diagnostic, MSD, Hizenpfizer and ZS Associates. With extensive experience in business strategy, medical affair, retail pharmacy & broad market, distribution and market access, key account management, business development and IVD.
Jim Hua

GM of Finance & Procurement

Mr. Jim Hua, General Manager of Finance & Procurement, is responsible for the company's internal finance and procurement operations. Mr. Jim Hua has over 18 years of experience in the finance field. Prior to joining Henlius, he served in various financial management roles at Hutchison Medi Pharma, Roche, and Johnson & Johnson. Mr. Jim Hua received a Bachelor's degree in Finance from Shanghai University in 2004 and his IMBA degree from Tongji University in 2011.
Jasmin Wang

Deputy General Manager of Quality

Deputy General Manager of Quality, Ms. Jasmin Wang, is responsible for the quality management of commercial manufacturing, clinical manufacturing and R&D. Ms. Wang graduated from East China University of Science and Technology and obtained a master of business administration degree from Fudan University. She has been in the biopharmaceutical industry for over 20 years and is mainly engaged in drug R&D, manufacturing and quality management.

Ms. Wang joined the Company in 2010 and successively served as QC, QA and manufacturing head. Ms. Wang has a deep understanding about drug regulations and antibody large-scale manufacturing and quality management. She plays a critical role in leading the GMP manufacturing and quality management of the Company.
Nancy Wang

Board Secretary

Ms. Nancy Wang, Board Secretary, is responsible for the organization of Shareholder General Meeting, Board Meeting and its committee meeting, and Supervisor Meeting as well as the information disclosure. She also takes charge of corporate branding and public relations. Previously, Ms. Wang has successively acted as Supervisor of the Marketing Department, Securities Affairs Representative and Manager of Public Affairs Department, Director of the Office of Board Secretary and Executive Director of Public Relations of the Company. Ms. Wang obtained her Bachelor’s degree in Bio-pharmacy from Nanjing Forestry University in 2010 and a Master’s degree in Biochemistry in 2013 from the same university.